Loading...
Pfizer Q2 2025 Earnings Report
Pfizer reported strong second-quarter 2025 results, driven by strengthened commercial execution and continued progress in its R&D pipeline, leading to a raise in its 2025 Adjusted diluted EPS guidance.
Key Takeaways
Pfizer delivered a robust second quarter in 2025, with revenues reaching $14.7 billion, marking a 10% operational increase year-over-year. The company's reported diluted EPS was $0.51, while adjusted diluted EPS stood at $0.78, reflecting a 30% increase. This strong performance led Pfizer to reaffirm its full-year 2025 revenue guidance and raise its adjusted diluted EPS guidance, demonstrating confidence in its strategic execution and operational efficiency.
Second-quarter 2025 revenues increased by 10% operationally year-over-year, reaching $14.7 billion.
Reported diluted EPS for Q2 2025 was $0.51, and Adjusted diluted EPS was $0.78, a 30% increase from the prior year.
Pfizer reaffirmed its full-year 2025 revenue guidance and raised its Adjusted diluted EPS guidance by $0.10.
The company is on track to achieve approximately $7.2 billion in overall anticipated net cost savings from previously announced cost improvement initiatives by the end of 2027.
Pfizer
Pfizer
Pfizer Revenue by Segment
Revenue by Segment
Biopharma Revenue
CapyFin.comPfizer CentreOne Revenue
CapyFin.comPfizer Ignite Revenue
CapyFin.com Forward Guidance
Pfizer reaffirmed its full-year 2025 revenue guidance and raised its Adjusted diluted EPS guidance, reflecting strong year-to-date performance, confidence in its business, and progress with cost improvement initiatives.
Positive Outlook
- Reaffirmed full-year 2025 Revenue guidance in a range of $61.0 to $64.0 billion.
- Raised full-year 2025 Adjusted diluted EPS guidance by $0.10 to a range of $2.90 to $3.10.
- Updated Adjusted diluted EPS guidance considers strong year-to-date performance and continued business confidence.
- Favorable impact from foreign exchange and progress with ongoing cost improvement initiatives are factored into the raised EPS guidance.
- Improvement in the effective tax rate on Adjusted income to approximately 13.0% (previously 15.0%).
Challenges Ahead
- The raised Adjusted diluted EPS guidance absorbs a one-time impact of approximately $0.20 related to the 3SBio transaction.
- Guidance includes a one-time $1.35 billion Acquired In-Process R&D charge related to the licensing agreement with 3SBio, Inc. to be recorded in Q3 2025.
- The company's guidance absorbs the impact of currently imposed tariffs from China, Canada, and Mexico.
- Potential price changes this year based on a letter received on July 31, 2025, from President Trump are absorbed in the guidance.
- Anticipated unfavorable revenue impact of approximately $0.5 billion due to recent and expected generic and biosimilar competition for certain products.